Results 81 to 90 of about 993 (163)

Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis. [PDF]

Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the
Pillar, Chris, Andrzejewski, Christina, Das, Anita, Castanheira, Mariana, Sandison, Taylor, Thompson, George, Bartizal, Ken, Locke, Jeffrey, Carvalhaes, Cecilia, Andes, David, Aram, Jalal, Pappas, Peter   +11 more
core   +1 more source

Novel Therapeutic Approaches to Invasive Candidiasis: Considerations for the Clinician

Infection and Drug Resistance, 2023
Frederic Lamoth1,2 1Infectious Diseases Service, Department of Medicine, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland; 2Institute of Microbiology, Department of Laboratory Medicine and Pathology, Lausanne University ...
Lamoth F
doaj  

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae [PDF]

Journal of Antimicrobial Chemotherapy, 2019
AbstractBackgroundRezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species.MethodsWe determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin
Tóth, Zoltán, Forgács, Lajos, Locke, Jeffrey B, Kardos, Gábor, Nagy, Fruzsina, Kovács, Renátó, Szekely, Adrien, Borman, Andrew M, Majoros, László   +8 more
openaire   +2 more sources

Breakthrough Tracheobronchial Aspergillosis Caused by Aspergillus calidoustus and Aspergillus niger in a Lung Transplant Recipient Despite Combined Antifungal Prophylaxis

Case Reports in Pulmonology, Volume 2026, Issue 1, 2026.
Aspergillus niger and Aspergillus calidoustus are relatively uncommon pathogens that could cause invasive disease, especially in immunocompromised patients. We present the case of a 61‐year‐old male with a history of idiopathic pulmonary fibrosis who was admitted to our hospital for a unilateral lung transplant that was performed without complications;
Carlos Enrique Calvache Benavides, Martha Daniela Rodríguez Cárdenas, Sergio Saul Sánchez Salazar, Rogelio de Jesús Treviño Rangel, Adrián Camacho Ortiz, Tun-Chieh Chen   +5 more
wiley   +1 more source

Long‐Term Use of Rezafungin: A Case Report and Insights Into Real‐World Access

Transplant Infectious Disease, EarlyView.
Jian Mei Li, Jacqueline E. Clark, Tiffany Wu   +2 more
wiley   +1 more source

Antifungal Resistance of Candida spp. Isolates From HIV/AIDS Patients in Iran 1999–2024: A Systematic Review and Meta‐Analysis

Journal of Clinical Laboratory Analysis, Volume 39, Issue 21, November 2025.
Antimicrobial resistance in Candida spp. is significant in individuals with HIV/AIDS infections, particularly in Iran. In this systematic review, a comprehensive systematic search was conducted to identify all the eligible studies between 1999 and 2024; the pooled resistance rates of Candida spp. against antimicrobial agents were estimated. The risk of
Aliasghar Fakhri‐Demeshghieh, Ali Yousefipour, Yousef Bolouki, Mohammad Sadegh Bigdeli, Erfan Zamani, Amirreza Farajkhoda, Alireza Salmani, Farzad Katiraee, Saied Bokaie   +8 more
wiley   +1 more source

Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trials. [PDF]

BACKGROUND: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with ...
Thompson, George R., Pullman, John, Nseir, Saad, Huang, Haihui, Pappas, Peter G., Girardis, Massimo, Sandison, Taylor, Thompson, George, Kullberg, Bart Jan, Thompson, George R, Bassetti, Matteo, Cornely, Oliver A, Pappas, Peter G, Manamley, Nick, Soriano, Alex, Kullberg, Bart, Honoré, Patrick, Cornely, Oliver, Kollef, Marin, Vazquez, Jose, Pappas, Peter   +20 more
core   +1 more source

Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials [PDF]

International audienceBackground: Invasive candidiasis/candidemia (IC/C) is associated with a substantial health economic burden driven primarily by prolonged hospital stay.
Fortún, Jesús, Cornely, Oliver A., Thompson, George R., Pullman, John, Sandison, Taylor, Thompson, George, Thompson, George R, Bassetti, Matteo, Dickerson, Sara, Cornely, Oliver A, Kollef, Marin H., Manamley, Nick, Honoré, Patrick M., Dupont, Herve, Honoré, Patrick, Cornely, Oliver, Bielicka, Inga, Kollef, Marin, Kollef, Marin H, Vazquez, Jose, Pappas, Peter, Honoré, Patrick M   +21 more
core   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin

Journal of Fungi
This mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff, Nathan P. Wiederhold   +1 more
doaj   +1 more source